Righetti G. (forthcoming). The Impact of Health Technology Assessment on Pharmaceutical Prices: Evidence from Germany. European Journal of Health Economics
Righetti, G. (2026). Regulação Farmacêutica em Contexto Internacional: Implicações para o SNS. Nova SBE, Social Equity Initiative – Health Economics Chair
Barros, P.P., Righetti, G., and Sá, L. (2026). "Most Favored Nation Drug Pricing: Anchoring to a Moving Target." Submitted to Health Affairs Forefront
Barros PP, Righetti G., and Sá L. (2025). Pricing Mechanisms for Multi-Indication Drugs. Available at https://papers.ssrn.com/abstract=5374679.
Gamba S., Pertile P., and Righetti G. (2025). Pricing Without Borders: Spillovers of External Reference Pricing in Pharmaceutical Regulation. Available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5381635. Under review
Barros PP, Righetti G., and Sá L. (2025). On the Long-Term Effects of Most Favored Nation Drug Pricing. Available at http://dx.doi.org/10.2139/ssrn.6373278. Submitted
"Escaping the External Reference Pricing Trap" with P. Pertile
"Mind the Gap: Toward an Equity-Conscious Pricing System for Multi-Indication Drugs ", with P.P. Barros, B. Haon, L. Sá, and L. Rochaix
"The Clinical Trial Balloon: How Strategic Eligibility Design Inflates Therapeutic Benefit of Cancer Drugs” with P.P. Barros, A. Gentilini, M. Miraldo, L. Sá, and C. Santos
“Losing Control: Patient Organizations and Retention in Randomized Clinical Trials”
“The Price of Choice: How Private Hospital Access Shapes Out-of-Pocket Spending” with P. Bertoli and C. Fertonani